NYSE:ATNM
Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.'s revenue was $90,000 in fiscal 2025. Free cash flow was −$24.7M, −27426.7% of revenue, and the diluted share count rose 3.7%.Summary generated from Actinium Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$90,000
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−40274.4%
Net margin−37652.2%
ROICn/a
Return on equity−167.0%
Debt / equityn/a
Free cash flow−$24.7M
FCF margin−27426.7%
Share count change+3.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 1 | 0 | n/a | 0 |
| Operating income | −25 | −34 | −52 | −42 | −36 |
| Net income | −25 | −33 | −49 | −38 | −34 |
| Free cash flow | −21 | 8 | −47 | −33 | −25 |
Recent filings
- 4Insider transaction report
Sep 4, 2026 - 4Insider transaction report
Sep 4, 2026 - 8-KNotice of delisting or listing-rule failure
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 7, 2026 - 8-KOther events
Jun 18, 2026 - 8-KNotice of delisting or listing-rule failure
May 29, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 8, 2026 - 10-KAnnual report for the fiscal year ended Dec 31, 2025
Mar 30, 2026